drugset / Trial / NCT07369284

Melatonin for Glycemic Control in Gestational Diabetes Mellitus

NCT07369284

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The goal of this randomized, double-blind, placebo-controlled clinical trial is to evaluate whether melatonin supplementation improves glycemic control in pregnant women diagnosed with gestational diabetes mellitus (GDM). The main question it aims to answer is: Does melatonin supplementation help with glycemic control, especially in lowering fasting plasma glucose level? Researchers will compare melatonin to a placebo (a look-alike substance that contains no melatonin) to see if melatonin works to improve glycemic control. Participants will: 1. Take melatonin or a placebo every day after randomization until delivery 2. Visit the antenatal clinic once every 1 to 2 weeks for follow-ups

Timeline

Start
2026-02
Primary completion
2027-06
Completion
2027-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Melatonin Small molecule 10 mg Oral

Indications